Cytotoxic Reactions
Cytotoxic Reactions - Related Videos
03:00
An Assay to Evaluate Immunodominance in Cytotoxic T Lymphocyte Responses
0 Views •
2025
The video showcases a flow cytometry-based assay for assaying immunodominance in cytotoxic T lymphocytes or CTL responses. Injected fluorescent target cells exhibit varying fluorescence corresponding to immunogenic epitopes. Post-spleen collection and sorting reveal a reduction in high-intensity fluorescent cells, confirming immunodominance in CTL responses.
11:14
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
0 Views •
Cited by 64 •
2013
A method for synthesis of air-sensitive titanium and vanadium anticancer agents is described, along with the evaluation of their cytotoxic activity towards human cancer cell line by the MTT Assay.
02:58
Evaluating Cytotoxicity and Membrane Integrity in Lung Slices via Lactate Dehydrogenase Assay
0 Views •
2025
This video demonstrates the lactate dehydrogenase, LDH assay to measure the cytotoxic effect of a test substance and its effect on the membrane integrity in human precision-cut lung slices. The assay provides a quantitative measure of cell death or damage in the sample.
02:55
An In Vitro Assay for Evaluating Natural Killer Cell Cytotoxicity against Cancer Cells
0 Views •
2025
This video demonstrates performing a lactate dehydrogenase release assay to determine the cytotoxicity of natural killer (NK) cells against the target cancer cells. The assay quantifies the release of the cytoplasmic lactate dehydrogenase enzyme from cancer cells by measuring the absorbance of the red-colored product formed.
06:08
A Flow Cytometry-Based Cytotoxicity Assay for the Assessment of Human NK Cell Activity
0 Views •
Cited by 57 •
2017
A flow cytometry-based method to quantitatively determine the cytotoxic activity of human natural killer cells is shown here.
FAQs
Antibody-mediated cytotoxicity can proceed through two distinct effector routes. Complement activation directly contributes to target-cell damage, whereas antibody-dependent cellular cytotoxicity recruits natural killer cells after antibodies recognize surface antigens. This distinction matters clinically because both pathways can eliminate infected or abnormal cells, yet they represent different mechanisms that may also contribute to immune-mediated tissue injury.
Cytotoxic T cells cause target-cell death by inducing apoptosis, or programmed cell death, through perforin and granzymes. This pathway differs from antibody-mediated mechanisms because it does not depend on complement activation or natural killer cell recruitment. Its clinical importance lies in removing infected or abnormal cells while directing injury toward cells displaying the recognized antigen.
Recognition depends on antigens displayed on cell surfaces, allowing antibodies or cytotoxic lymphocytes to identify particular targets. After recognition, the effector pathway determines the type of injury: antibodies may activate complement or recruit natural killer cells, whereas cytotoxic T cells induce apoptosis. Surface-antigen recognition therefore connects immune specificity with selective cellular damage.
During an incompatible blood transfusion, immune recognition of antigens on transfused cell surfaces can activate cytotoxic pathways against those cells. Antibodies may promote complement-mediated damage or recruit natural killer cells through antibody-dependent cellular cytotoxicity. This example shows why identifying antigen compatibility is important for reducing the risk of harmful immune responses in transfusion medicine.
Cytotoxic reactions may become harmful when immune mechanisms directed against target cells injure the host instead of removing only infected or abnormal cells. The overview identifies autoimmune hemolytic anemia and some drug-induced cytopenias as examples, while incompatible blood transfusions represent a transfusion-medicine concern. These conditions illustrate how normal defense mechanisms can contribute to immune-mediated disease.
Mechanistic understanding helps clinicians connect antibody or cytotoxic-lymphocyte activity with cellular injury, supporting diagnosis and risk assessment. It also clarifies whether complement activation, natural killer cell recruitment, or cytotoxic T-cell apoptosis may be relevant to the clinical problem. This knowledge contributes to developing targeted therapies for conditions involving excessive or misdirected cytotoxic activity.